Also Known As
LY3437943 · Triple G
Overview
Retatrutide is a novel triple incretin agonist in clinical trials. Targets GIP, GLP-1, and glucagon receptors for enhanced metabolic effects.
Mechanism of Action
Activates GIP, GLP-1, and glucagon receptors simultaneously. The glucagon component may enhance energy expenditure and fat oxidation.
Quick Reference
Notes
Currently in Phase 3 trials. Shows greater weight loss than dual agonists in studies.
Dosing Protocol
Pharmacokinetics
Administration
Special Instructions
Currently in Phase 3 clinical trials. Titrate slowly over 24-48 weeks to target dose.
Warnings
Contraindications
Drug Interactions
Possible Side Effects
Legal & Regulatory
Pregnancy
Molecular Data
No sources available yet.
Related Peptides
No community data available yet. Be the first to add this peptide to your inventory!